CD19 News

News

Tafasitamab Plus Lenalidomide Prolongs OS in Relapsed/Refractory DLBCL: RE-MIND2

06/20/2022

Janelle Bradley

Tafasitamab plus lenalidomide prolonged OS compared to bendamustine plus rituximab or rituximab plus gemcitabine and oxaliplatin for patients with relapsed/refractory DLBCL in the RE-MIND2 study.

Tafasitamab plus lenalidomide...

06/20/2022

Oncology

News

Axicabtagene Ciloleucel Significantly Improves Outcomes Over Standard Care as Second-Line Therapy for Large B-cell Lymphoma

05/13/2022

John Otrompke

Findings from the ZUMA-7 trial suggest axicabtagene ciloleucel is an effective alternative option for the second-line treatment of relapsed or refractory large B-cell lymphoma.

Findings from the ZUMA-7 trial...

05/13/2022

Oncology

News

Pembrolizumab May Reinvigorate T-Cells in CAR-T Patients Who Relapse

04/07/2022

John Otrompke

Pembrolizumab was shown to reverse T-cell exhaustion for patients with B-cell lymphomas who did not respond well to CD19-targeted CAR T-cell therapy.

Pembrolizumab was shown to...

04/07/2022

Oncology

News

Dual CAR-T Therapy Associated With High Remission in R/R B-Cell ALL

03/09/2022

John Otrompke

Tandem CD19 and CD22 dual target CAR-T cells have been developed to achieve a CR in patients with R/R B-ALL.

Tandem CD19 and CD22 dual target...

03/09/2022

Oncology

News

Anti-CD19 CAR-T Therapy Superior to Standard of Care as Second-Line Treatment for DLBCL

03/02/2022

Results of the phase 3 ZUMA-7 trial confirm axicabtagene ciloleucel had superior EFS to second-line chemoimmunotherapy, standard of care for R/R DLBCL.

Results of the phase 3 ZUMA-7...

03/02/2022

Oncology

News

Tisagenlecleucel Shows Similar Effects to Standard Care for DLBCL

02/28/2022

In an international phase 3 trial, second-line tisagenlecleucel was not superior to salvage therapy for refractory DLBCL.

In an international phase 3...

02/28/2022

Oncology

News

Prophylactic Anakinra Prevents CRS, ICANS in Patients With LBCL Receiving CAR T-cells

02/02/2022

IL-1 receptor inhibitor anakinra demonstrates feasibility in the prevention of CRS and ICANS in patients with LBCL and MCL who receive commercial CD19 CAR T-cells.

IL-1 receptor inhibitor anakinra...

02/02/2022

Oncology

News

FDA Approves Brexucabtagene Autoleucel CAR-T Therapy for R/R B-ALL

10/04/2021

On October 1, 2021, the FDA approved brexucabtagene autoleucel for the use in the treatment of adult patients with R/R B-ALL.

On October 1, 2021, the FDA...

10/04/2021

Oncology

News

Type of Anti-CD19 CAR-T Infusion Impacts Safety, Efficacy in Patients With LBCL

10/22/2020

Clinical study findings suggest that heterogeneity of CAR T-cell infusion products affect the efficacy and toxicity of axi-cel therapy in patients with large B cell lymphoma.

Clinical study findings suggest...

10/22/2020

Oncology

News

Higher CART-19 Dosage More Effective at Inducing CR in Relapsed or Refractory CLL

09/23/2020

Findings from a study of CART-19 have established an effective dose for inducing complete responses with reduced toxicity in relapsed/refractory CLL.

Findings from a study of CART-19...

09/23/2020

Oncology

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology